Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tinlarebant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Belite Bio Gets Conditional UK Approval For Tinlarebant
    Belite Bio Gets Conditional UK Approval For Tinlarebant

    02 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/02/3178795/0/en/Belite-Bio-Announces-UK-s-Medicines-and-Healthcare-Products-Regulatory-Agency-Agrees-to-Conditional-Marketing-Authorization-Application-Based-on-Interim-Analysis-Results-for-the-Tr.html

    GLOBENEWSWIRE
    02 Nov 2025
    Share Share
    Belite Bio Gets Priority Review From China NMPA For Tinlarebant
    Belite Bio Gets Priority Review From China NMPA For Tinlarebant

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3167044/0/en/Belite-Bio-Announces-China-NMPA-Agrees-to-New-Drug-Application-with-Priority-Review-based-on-Interim-Analysis-Results-for-the-Treatment-of-Stargardt-Disease-with-Tinlarebant.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    Belite Ends 2-Year Ph 3 Tinlarebant Trial in Stargardt Disease
    Belite Ends 2-Year Ph 3 Tinlarebant Trial in Stargardt Disease

    12 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/12/3149167/0/en/Belite-Bio-Announces-Completion-of-DRAGON-a-2-Year-Phase-3-Trial-of-Oral-Tinlarebant-in-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    12 Sep 2025
    Share Share
    Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial
    Belite Bio Completes Enrollment in Global Phase 3 PHOENIX Trial

    02 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/02/3108920/0/en/Belite-Bio-Announces-Completion-of-Enrollment-in-the-Pivotal-Global-Phase-3-PHOENIX-Trial-Evaluating-Oral-Tinlarebant-in-Geographic-Atrophy.html

    GLOBENEWSWIRE
    02 Jul 2025
    Share Share
    Belite Gets Breakthrough For Tinlarebant In Stargardt Diseases
    Belite Gets Breakthrough For Tinlarebant In Stargardt Diseases

    21 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/21/3085441/0/en/Belite-Bio-Announces-FDA-Granting-of-Breakthrough-Therapy-Designation-for-Tinlarebant-for-the-Treatment-of-Stargardt-Disease.html

    GLOBENEWSWIRE
    21 May 2025
    Share Share
    Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease
    Belite’s Ph 3 Trial Shows Tinlarebant Benefits In Stargardt Disease

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3033536/0/en/Belite-Bio-Announces-Interim-Analysis-Results-from-the-Pivotal-Global-Phase-3-DRAGON-trial-of-Tinlarebant-in-Adolescent-Stargardt-Disease-Subjects.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share